Rekvina Laboratories' public shareholders have an exit opportunity with an open offer at ₹25 per share. The offer, covering 26% of expanded capital, runs from July 1 to July 14, 2026. An Independent Directors Committee deems the price fair, but acquirers face property dispute disclosures.
Rekvina Laboratories Open Offer to Acquire 26% Stake at ₹25 Per Share
Rekvina Laboratories Limited is set to see a significant ownership change as an open offer commences to acquire 26% of its expanded share capital at ₹25 per share. The offer will be open from July 01, 2026, to July 14, 2026.
Reader Takeaway: Shareholders get a clear exit at ₹25, but acquirers' legal issues raise governance questions.
What just happened
Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel are launching an open offer to acquire 2,890,100 shares, representing 26% of Rekvina Laboratories' expanded share capital. The offer price is fixed at ₹25 per share, with a face value of ₹5 per share.
The Committee of Independent Directors (IDC) has reviewed the proposal and issued a report on June 09, 2026, stating that the offer price of ₹25 is fair and reasonable.
Why this matters
This open offer provides an opportunity for existing public shareholders of Rekvina Laboratories to exit their investment at a predetermined price. The offer is not conditional on achieving a minimum acceptance level, ensuring it will proceed regardless of the number of shares tendered.
The fairness opinion from the Independent Directors provides a degree of comfort regarding the valuation of the offer.
The backstory
The acquirers, Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel, have disclosed certain legal proceedings. Specifically, an FIR was filed on April 18, 2026, concerning an alleged illegal property transfer. Additionally, another FIR dated June 11, 2026, was filed against Acquirer 2 (Amit Mukesh Shah) related to property disputes.
These disclosures are part of the regulatory requirements for transparency in open offers.
What changes now
Upon successful completion of the open offer, the acquirers will hold a substantial stake (26%) in Rekvina Laboratories, potentially leading to a change in management and strategic direction. Shareholders who accept the offer will receive ₹25 per share and realize their investment.
Risks to watch
Investors should be aware of the disclosed FIRs against the acquirers concerning property disputes. While the Independent Directors have deemed the offer price fair, these legal issues could potentially impact future governance or business operations of Rekvina Laboratories.
Peer comparison
[No verifiable peer comparison data available in the filing.]
Context metrics
The tendering period for the open offer is from July 01, 2026, to July 14, 2026. Shareholders can expect payment or completion of the transaction by July 28, 2026, with a post-open offer announcement expected on August 04, 2026.
What to track next
Investors should monitor the response to the open offer and any further developments related to the legal proceedings involving the acquirers. The effectiveness of the new management, if any, will be key post-offer.